Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 11/20 | 0.69 |
| ▸ | CASP3 | P42574 | 11/20 | 0.63 |
| ▸ | SENP8 | Q96LD8 | 11/20 | 0.63 |
| ▸ | SENP7 | Q9BQF6 | 11/20 | 0.63 |
| ▸ | SENP6 | Q9GZR1 | 11/20 | 0.63 |
| ▸ | TDP2 | O95551 | 4/20 | 0.63 |
| ▸ | NSD2 | O96028 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.58 |
| ▸ | POLB | P06746 | 7/20 | 0.58 |
| ▸ | CASP6 | P55212 | 7/20 | 0.58 |
| ▸ | CASP8 | Q14790 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | CASP9 | P55211 | 5/20 | 0.58 |
| ▸ | CASP7 | P55210 | 3/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1483376 | 0.81 | ALDH1A1 (0.55) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL7018973 | 0.80 | HDAC3 (0.73) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL8114534 | 0.80 | CASP3 (0.54) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL25725335 | 0.79 | CASP3 (0.67) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL11654868 | 0.79 | CASP3 (0.53) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL27938343 | 0.78 | SMN1; SMN2 (0.54) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL31330145 | 0.78 | MITF (0.47) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL11480640 | 0.77 | ATM (0.55) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL20464026 | 0.77 | L3MBTL1 (0.48) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL11460500 | 0.77 | MITF (0.55) | L3MBTL1CASP3SENP8SENP7SENP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117298108-A | Androgen receptor and glucocorticoid receptor dual-target inhibitor and application thereof | 浙江师范大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-107616976-B | A kind of pharmaceutical composition of Raltitrexed and preparation method thereof | 南京正大天晴制药有限公司 | 2019-06-21 | — | — | CN | disclosed |
| US-20110178074-A1 | ANTIPATHOGENIC BENZAMIDE COMPOUNDS | GENESOFT PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7498405-B2 | Halogen-substituted thienyl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498405-B2 | Halogen-substituted thienyl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| EP-1236712-B1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20050154048-A1 | Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2005-07-14 | — | — | US | disclosed |
| US-6710056-B2 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. | AJINOMOTO CO., INC. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | AJINOMOTO CO. INC (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1236712-A1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-4382143-A | Hypolipidemic and antiatherosclerotic novel (monosubstituted-amino)heteroaryl carboxylic acids and analogs | AMERICAN CYANAMID COMPANY (US) | 1983-05-03 | — | — | US | disclosed |
| US-4219482-A | Process for preparing thiophene and furan derivatives | LABAZ (FR) | 1980-08-26 | — | — | US | disclosed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | IRF3, BCL3, L3MBTL3 | L3MBTL1 69/4885CASP3 6/4885SENP8 4735/4885 |
| US-20050154048-A1 | Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use | CTSZ, CTSE, CTSS | L3MBTL1 4689/4885CASP3 669/4885SENP8 282/4885 |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | HABP2, F2, F7 | L3MBTL1 2972/4885CASP3 1237/4885SENP8 921/4885 |
| US-20110178074-A1 | ANTIPATHOGENIC BENZAMIDE COMPOUNDS | CASP3, BCL3, ME3 | L3MBTL1 143/4885CASP3 1/4885SENP8 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.